Shin Nippon Biomedical Laboratories, Ltd.
Transformation 2030
Announced the new medium-term management plan "Transformation 2030." Aims for net sales of 70 hundred million yen or more and ordinary income of 20 hundred million yen or more in FY2030 through expansion of the CRO business and monetization of the TR business. Will strengthen DX/AX initiatives and globalization, pursuing sustainable growth anchored by four growth engines.
Key Figures
- Net Sales: 70 hundred million yen or more (FY2030 target)
- Ordinary Income: 20 hundred million yen or more (FY2030 target)
- ROE: 10% or more (FY2030 target)
AI要約
Overview of Transformation 2030
The new medium-term management plan "Transformation 2030" was presented, setting financial targets of net sales of 70 hundred million yen or more, ordinary income of 20 hundred million yen or more, and ROE/ROIC of 10% or more. Centered on DX/AX promotion and globalization, the plan strengthens the revenue structures of the CRO and TR businesses and positions four growth engines—nonclinical/clinical CRO, TR business, DX/AX, and globalization—as pillars for expansion.
Growth Engines and Business Structure
Transformation 2030 will drive mid-term growth through four growth engines. The first engine is achieving a dominant CRO position; the second is commercialization and monetization of the TR business; the third is promotion of DX/AX and globalization; and the fourth is deepening new domains and business collaborations. Through these, the company intends to build and expand revenue streams across both CRO and TR.
Shin Nippon Biomedical Laboratories, Ltd.
Company overview · Stock price · Financial data · All IR
